Is Elanco Animal Health Incorporated (ELAN) a Buy, Sell, or Hold?
Elanco Animal Health Incorporated
NYSE:ELAN
$25.54 USD
-$0.01 (-0.04%)
- Volume
- 3.31M
- Average Volume
- 5.78M
- Market Capitalization
- $12.76B
- P/E Ratio
- -51.31
- Dividend Yield
- 0.00%
- Price Target
- $30.00
- Year High
- $27.72
- Year Low
- $13.39
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.16
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Jeffrey N. Simmons |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | ELAN |
| CUSIP | 28414H103 |
| CIK | 0001739104 |
| Web | https://www.elanco.com |
| Phone | 877 352 6261 |
| Currency | USD |
| Employees | 9900 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.61 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.16 |
| Quick Ratio | 1.12 |
| Cash Ratio | 0.26 |
Sales & Book Value
| Annual Sales | $4.72B |
| Price / Sales | 2.61 |
| Cash Flow | 0.63 |
| Price / Cash Flow | 40.50 |
| Price / Book | 1.96 |
Price Target and Rating
| Average Stock Price Forecast | $30.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $23.00 |
| Forecast Upside/Downside | -14.87% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 21 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.47 |
| Trailing P/E Ratio | -51.31 |
| PEG Ratio | 0.32 |
| P/E Growth | 0.32 |
| Net Income | $-232M |
| Net Margin | -4.95% |
| Pretax Margin | -4.03% |
| Return on Equity | -3.64% |
| Return on Assets | -1.83% |
Financials Score
| AltmanZ Score | 1.46 |
| Piotroski Score | 5.00 |
| Working Capital | 1.92B |
| Total Assets | 13.22B |
| Ebit | 73M |
| Market Cap | 12.62B |
| Total Liabilities | 6.72B |
Poll Results
About Elanco Animal Health Incorporated (NYSE:ELAN) Stock
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aqu ... aculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report?
2026-07-15 13:10:25
Elanco Animal Health (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement
2026-07-08 08:00:00
INDIANAPOLIS, July 8, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2026 financial results on Wednesday, August 5, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.
Is the Options Market Predicting a Spike in Elanco Animal Health Stock?
2026-06-30 13:40:22
Investors need to pay close attention to ELAN stock based on the movements in the options market lately.
2026-06-18 07:26:00
New corporate venture capital platform will invest to advance therapeutics, technologies and One Health solutions INDIANAPOLIS, June 18, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced plans to establish Elanco Ventures, a dedicated corporate venture capital (CVC) platform designed to support, invest and advance innovation in animal health. To be backed by a $25 million multi-year commitment, Elanco Ventures will initially focus on strategic investments in therapeutic advancements and supportive technologies across the animal health sector.
2026-06-15 08:47:00
TruCan Ultra Lyme-L4 is the first and only 1/2 mL combination vaccine protecting against both Lyme disease and leptospirosis, all in a low-volume dose By combining two injections into one, the vaccine minimizes "pokes" supporting comfortable wellness visits for pets Features proprietary PureFil™ Technology, designed to reduce vaccination reactions associated with unwanted proteini , ii , iii Product expected to begin shipping in the next 30 days INDIANAPOLIS, June 15, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Department of Agriculture (USDA) approval of TruCan Ultra Lyme-L4, expanding its extensive TruCan Ultra Portfolio of comfortable and convenient combination vaccines. This milestone marks the introduction of the first and only 1/2 mL combination vaccine designed to protect dogs against both Lyme disease and leptospirosis, two increasingly prevalent threats to canine health.
Elanco CEO on rolling out New World screwworm vaccine: 'We're prepared'
2026-06-04 19:23:21
Jeffrey Simmons, Elanco, joins 'Closing Bell Overtime' to talk producing a vaccine for the New World Screwworm infection in cattle in the U.S.
2026-06-04 06:26:00
Company offers portfolio of treatment options and expert guidance following first confirmed case in the United States New World screwworm has officially reached the United States, with the first confirmed case in U.S. livestock in Texasi New World screwworm can infest any warm-blooded animals – including livestock and pets – posing a significant threat to animal health, welfare, and producer livelihood Elanco offers a portfolio of options for both livestock and pets that can treat infestations caused by New World screwworm larvae INDIANAPOLIS , June 4, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reaffirms its commitment to providing veterinarians, livestock producers, and pet owners with resources and treatment options for their animals against the escalating threat posed by New World screwworm (NWS). The fly recently reached the United States, with the first case confirmed in U.S. livestock in Texas.i The emergence of New World screwworm in the U.S. creates a threat for veterinarians, livestock producers and pet owners that has not been seen north of the Florida Keys since the fly was eradicated from the United States more than 50 years ago.ii New World screwworm (Cochliomyia hominivorax) larvae feed on living tissue and can affect a wide range of warm-blooded animals, including livestock, companion animals, wildlife, and even humans.ii "New World screwworm could have a devastating impact on animal health, welfare, and producer livelihoods," said Jeff Simmons, President and CEO, Elanco Animal Health.
Jim Cramer Says He Feels 'Something Not Well' At Zoetis, Names A Rival As His Pick
2026-06-03 08:05:12
On CNBC's “Mad Money Lightning Round,” Jim Cramer said about Zoetis Inc (NYSE:ZTS) that he feels "something not well there."
Frequently Asked Questions
-
What is the current Elanco Animal Health Incorporated (ELAN) stock price?
-
Elanco Animal Health Incorporated(NYSE:ELAN) stock price is $25.54 in the last trading session. During the trading session, ELAN stock reached the peak price of $27.72 while $13.39 was the lowest point it dropped to. The percentage change in ELAN stock occurred in the recent session was --0.04% while the dollar amount for the price change in ELAN stock was -$-0.01.
-
ELAN's industry and sector of operation?
-
The NYSE listed ELAN is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of ELAN?
-
Ramiro Martin Cabral | Executive Vice President & President of Elanco International
Timothy J. Bettington | Executive Vice President of Center of Strategic Growth
Ellen de Brabander | Executive Vice President of Research, Development & Regulatory Affairs
Jeffrey N. Simmons | President, Chief Executive Officer & Director
David S. Kinard | Executive Vice President of Human Resources, Corporate Communications & Administration -
How many employees does ELAN have?
-
Number of ELAN employees currently stands at 9900. ELAN operates from 2500 Innovation Way, Greenfield, IN 46140, US.
-
Link for ELAN official website?
-
Official Website of ELAN is: https://www.elanco.com
-
How do I contact ELAN?
-
ELAN could be contacted at phone #877 352 6261 and can also be accessed through its website. ELAN operates from 2500 Innovation Way, Greenfield, IN 46140, US.
-
How many shares of ELAN are traded daily?
-
The average number of ELAN shares traded daily for last 3 months was 5.78M.
-
What is the market cap of ELAN currently?
-
The market value of ELAN currently stands at $12.76B with its latest stock price at $25.54